Meningococcus vaccines
AssigneeGlaxosmithkline Biologicals SA
InventorsAlessia BIOLCHI, Brunella BRUNELLI, Marzia GIULIANI, Vega MASIGNANI
Life of this patent
Estimating the term…
Abstract
Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.
Claims21
1-15. (canceled)
A method for protecting a mammal against a meningococcal infection, comprising administering to the mammal an immunogenic composition comprising a fusion polypeptide comprising all three of v1, v2 and v3 meningococcal fHbp, in combination with one or more of (i) a NHBA polypeptide (ii) a NadA polypeptide and/or (iii) meningococcal outer membrane vesicles (OMVs).
An immunogenic composition comprising meningococcal outer membrane vesicles in combination with one or more of (i) a NHBA polypeptide (ii) a NadA polypeptide and/or (iii) a fusion polypeptide comprising all three of v1, v2 and v3 meningococcal fHbp;
- wherein the outer membrane vesicles (OMVs) are present at a concentration between 5-30 μg/ml.
Dependencies are inferred from the claim text.